Document Type
Article
Publication Date
11-21-2017
Abstract
Cancer immunotherapy has transformed the treatment of cancer. However, increasing use of immune-based therapies, including the widely used class of agents known as immune checkpoint inhibitors, has exposed a discrete group of immune-related adverse events (irAEs). Many of these are driven by the same immunologic mechanisms responsible for the drugs' therapeutic effects, namely blockade of inhibitory mechanisms that suppress the immune system and protect body tissues from an unconstrained acute or chronic immune response. Skin, gut, endocrine, lung and musculoskeletal irAEs are relatively common, whereas cardiovascular, hematologic, renal, neurologic and ophthalmologic irAEs occur much less frequently. The majority of irAEs are mild to moderate in severity; however, serious and occasionally life-threatening irAEs are reported in the literature, and treatment-related deaths occur in up to 2% of patients, varying by ICI. Immunotherapy-related irAEs typically have a delayed onset and prolonged duration compared to adverse events from chemotherapy, and effective management depends on early recognition and prompt intervention with immune suppression and/or immunomodulatory strategies. There is an urgent need for multidisciplinary guidance reflecting broad-based perspectives on how to recognize, report and manage organ-specific toxicities until evidence-based data are available to inform clinical decision-making. The Society for Immunotherapy of Cancer (SITC) established a multidisciplinary Toxicity Management Working Group, which met for a full-day workshop to develop recommendations to standardize management of irAEs. Here we present their consensus recommendations on managing toxicities associated with immune checkpoint inhibitor therapy.
Recommended Citation
Puzanov, I.; Diab, A.; Abdallah, K.; Bingham, C. O.; Brogdon, C.; Dadu, R.; Hamad, L.; Kim, S.; Lacouture, M. E.; LeBoeuf, N. R.; Lenihan, D.; Onofrei, C.; Shannon, V.; Sharma, R.; Silk, A. W.; Skondra, D.; Suarez-Almazor, M. E.; Wang, Y.; Wiley, K.; Kaufman, H. L.; Ernstoff, M. S.; Anderson, J.; Lehman, K.; Reshef, D.; Saylors, A.; Turner, M.; Waxman, I.; Arrindell, D.; Andrews, S.; Ballesteros, J.; Boyer, J.; Cotarla, I.; Dawson, M.; Goswami, T.; Hayreh, V.; Holmes, W.; Rasheed, Z.; Sarkeshik, M.; Schreiber, J.; Shafer-Weaver, K.; Chen, D.; Ley-Acosta, S.; Chonzi, D.; Go, W.; Cunha, R.; Gulley, J. L.; Wood, L.; Davies, M.; Dicker, Adam; Eifler, L.; Gregory, N.; Ferguson, A.; Ferlini, C.; Frankel, S.; Gochett, C.; Goldberg, J.; Patel, K.; Wariabharaj, D.; Goncalves, P.; Helie, N.; Hsu, J. Y.; Ibrahim, R.; Larocca, C.; Lambotte, O.; Luke, J.; McClure, J.; Michelon, E.; Nakamura, M.; Piperdi, B.; Riemer, J.; Robert, C.; Sharfman, W.; Sharon, E.; Sherry, R.; Simonson, C.; Thomas, C.; Trehu, E.; Thompson, J. A.; Tresnan, D.; Zhang, L.; and Zheng, P., "Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group." (2017). Department of Radiation Oncology Faculty Papers. Paper 99.
https://jdc.jefferson.edu/radoncfp/99
Creative Commons License
This work is licensed under a
Creative Commons Public Domain Dedication 1.0 License.
PubMed ID
29162153
Comments
This article has been peer reviewed. It is the author’s final published version in Journal for ImmunoTherapy of Cancer
Volume 5, Issue 1, November 2017, Article number 95
The published version is available at DOI: 10.1186/s40425-017-0300-z. Copyright © Puzanov et al.